At 200-400 mg AM (SHR-5 or equivalent):

• Onset: 30-90 min. Tmax for salidroside ~1 hr; salidroside has 32-98% oral bioavailability depending on extract quality and fed/fasted state (per community-data block).
• Peak: 2-4 hours. Subjectively a background lift, not a stimulant rush — closer to "I forgot I was tired" than "I'm wired."
• Plateau: 4-8 hours of mild fatigue-resistance and cognitive smoothness.
• Taper: Gradual; rhodiola has multiple active metabolites with effective half-lives 3-8 hr depending on the constituent. By ~10-12 hr post-dose it's gone.

Characteristic effects (Dylan's archetype reading):

• More noticeable under stress or sleep-debt than at baseline — this is the adaptogen pattern. A well-rested user on a low-load day may notice ~30% of what they'd notice on a high-load day.
• Mental clarity and word-finding feels easier — useful for client calls, business writing, BJJ technique drilling.
• Mild stimulation subset (~15-20% of users) feel slightly wired — useful AM, avoid PM dosing.
• Fatigue floor — there's a felt-floor under exhaustion; the bottom of the day's energy curve doesn't drop as far.
• Anxiety reduction in stress-driven anxiety (cognitive-load anxiety, deadline anxiety); less effect on trait anxiety.
• No euphoria, no abuse liability, no comedown. Very few users describe missing it.

Honest variability: ~5-10% of users feel nothing (likely extract-quality issue + first-pass metabolism variance); ~10-15% feel mild jitter and prefer to skip; ~70-85% report consistent mild benefit. Almost no one reports a strong effect — this is not a stimulant.

For Dylan at 250 mg AM (Nature's Way): you should be feeling the baseline lift during 12-hour business-owner days and post-training cognitive recovery. If not noticeable after 6-8 weeks, the most likely cause is extract quality (Nature's Way isn't SHR-5-verified); switch to Now Foods Rhodiola 500 mg (standardized 3% rosavins/1% salidrosides) for a controlled A/B test before concluding "non-responder."

• Tolerance buildup: Minimal. Most users report sustained effect over months. No receptor-downregulation mechanism predicted from the polypharmacology.
• Recommended cycle: Daily continuous use is fine and what most users do. Some practitioners cycle 8 weeks on / 2 weeks off as standard adaptogen hygiene; the evidence for needing a cycle is weak but it's a cheap insurance policy. Dylan's fit-criteria are coded for 8 weeks on / 2 weeks off — defensible but not strictly necessary.
• The "Russian intermittent" protocol: 4-6 weeks on / 1 week off — older traditional pattern; no clinical data supports it over continuous use.
• Reset protocol if effect fades: Likely not pharmacological tolerance — more probably (1) extract degradation (rhodiola loses potency with heat/humidity over 12-18 months), (2) sleep-debt creep masking benefit, (3) novelty fade. Try (a) fresh bottle from verified vendor, (b) 1-2 week washout, (c) dose increase to 500 mg before assuming the molecule stopped working.

Synergistic with

• caffeine (Dylan's V4 onboarding): Different mechanism (rhodiola = monoaminergic; caffeine = adenosine antagonist) → additive lift without doubling cardiovascular load. 200 mg rhodiola + 100-200 mg caffeine is a classic morning stack.
• l-theanine 200 mg: Smooths any rhodiola stimulation; covers the ~15-20% jitter-sensitive subset.
• modafinil: Compatible. Rhodiola covers HPA-axis stress component; modafinil hits histamine/orexin. No mechanistic overlap; clinical reports support synergy. No serotonin-syndrome risk at OTC rhodiola doses given mild MAO-A inhibition magnitude.
• ashwagandha: Opposite adaptogen profile — rhodiola = pro-energy AM; ashwagandha = anxiolytic/cortisol PM. Logical AM/PM pairing. No mechanism conflict.
• bacopa: Different adaptogen class (BDNF/cholinergic vs monoamine/HPA). Sometimes combined for "comprehensive adaptogen" stacks; no contraindication.
• l-tyrosine: Tyrosine is the dopamine precursor; rhodiola mildly inhibits MAO-A → both push the dopamine arm of the stress response. Useful under acute high-cognitive-load (deadline night, fight camp).
• creatine: Neutral but commonly co-stacked; combined endurance + cognitive evidence base for resistance-trained users (Koozehchian 2025 was creatine-naive but the population overlaps).
• NAC, curcumin (V4): Antioxidant convergence; rhodiola's NRF2 activation complements direct antioxidants.

Avoid stacking with

• MAOIs (phenelzine, tranylcypromine, moclobemide): Theoretical additive monoamine effect — rhodiola's mild MAO-A inhibition could compound. Hard block.
• SSRIs/SNRIs at high doses: Serotonin-syndrome theoretical signal. Clinical risk is low (Mao 2015 used rhodiola alongside sertraline-comparator with no AEs) but monitor for tremor, hyperthermia, autonomic instability if high-dose SSRI + high-dose rhodiola.
• Other stimulant-class compounds at high dose: Additive sympathetic load; usually not dangerous but uncomfortable.
• Selegiline at MAO-B doses (1-2.5 mg): Likely fine — MAO-B vs MAO-A is the relevant axis. At doses >10 mg/day where selegiline loses selectivity, treat as MAOI.

Neutral / safe co-administration

• All V4/V5 stack compounds for Dylan: magnesium, NAC, citicoline, alpha-GPC, omega-3 DHA, vitamin D3/K2, beta-alanine, creatine, glycine, vitamin C — no interactions known.
• BPC-157, TB-500, Semax, Selank, other research peptides — neutral.
• Standard 23andMe-relevant CYP polymorphisms — rhodiola's hepatic metabolism is via UGT (glucuronidation) primarily; CYP involvement is minor.

• MAOIs: Theoretical additive MAO-A inhibition. Avoid co-administration.
• SSRIs/SNRIs: Likely safe at OTC rhodiola doses but theoretical serotonin signal — monitor in high-dose combinations.
• Stimulants (amphetamine, methylphenidate, modafinil): Additive CNS stimulation. Modafinil + rhodiola is well-tolerated; amphetamine + rhodiola may feel like over-stimulation.
• Anticoagulants (warfarin, DOACs): In vitro signal for platelet effect but no clinical bleeding events reported. Routine monitoring if concurrent warfarin.
• CYP3A4 substrates: Weak in vitro CYP inhibition signals; clinically minor at OTC doses. Not a meaningful interactor compared to St. John's Wort or grapefruit.
• Antidiabetic drugs (metformin, sulfonylureas): Rhodiola has mild hypoglycemic signal in animal models — clinically negligible at OTC dose, but worth monitoring blood glucose in T2DM patients adding rhodiola.
• Hormonal contraceptives: No documented interaction. Unlike modafinil (CYP3A4 inducer), rhodiola does not compromise OCP efficacy.

Not well characterized. Salidrosides and rosavins are primarily UGT-glucuronidated and excreted renally; CYP involvement is secondary.

• UGT1A polymorphisms: May affect salidroside clearance — no clinical implications established.
• MAO-A polymorphisms (uVNTR, the "warrior/worrier" locus): Theoretical — low-activity MAO-A carriers (~30% of male populations) might be more sensitive to rhodiola's MAO-A inhibition. Not validated in trials.
• COMT Val158Met: Theoretical — Val/Val ("warriors") might respond more robustly given faster dopamine clearance at baseline. Same logic as the modafinil COMT speculation; not specifically tested in rhodiola.
• CYP2D6: Not a primary metabolizer of salidrosides/rosavins. PM status unlikely to affect rhodiola exposure.

For Dylan post-23andMe (June 2026): the only actionable pharmacogenomic signal is COMT — Val/Val phenotype would suggest staying with continuous daily dosing; Met/Met might be a candidate for lower dose (100 mg) to avoid the anxiety-prone subset signal. Not high-priority data.

For Dylan: Stay on Nature's Way 250 mg/day for now (current bottle). If subjective effect plateaus at 8 weeks or business/training load steps up, switch to Now Foods Rhodiola 500 mg/day (1 cap) or 250 mg BID as a controlled extract-quality test. Total annual cost: $60-90 — negligible.

• Baseline (before starting or before dose change):
  • Subjective fatigue (Fatigue Assessment Scale, FAS — 10-item, free)
  • Perceived stress (PSS-10 — Cohen's Perceived Stress Scale)
  • Sleep quality (Karolinska Sleepiness Scale or simple 1-10 daily VAS, 7-day baseline)
  • Morning cortisol (salivary; CAR — cortisol awakening response — gold standard but lab-dependent)
  • Mood (PHQ-9 if any depression signal)
• During use:
  • Same metrics at 4 weeks (acute response) and 12 weeks (durability)
  • Weeks 1-2: Daily sleep-onset latency, AM jitter VAS — catch the stim-sensitive subset early
  • Resting HR + BP (home cuff, 3-day average) — rhodiola is cardiovascular-neutral but verify in n=1
  • Performance metrics if endurance protocol: 10K run time, 5RM bench, HRV recovery overnight
• Post-cycle (if cycling): Not strictly applicable for continuous use. If discontinued for >2 weeks, compare same baseline metrics — expect 70-85% of users to feel "slightly worse" off vs on.